Dronedarone (development codename SR33589 and marketed as Multaq) is a drug by Sanofi-Aventis, mainly for the indication of cardiac arrhythmias. It was approved by the FDA on July 2, 2009. It was recommended as an alternative to amiodarone for the treatment of atrial fibrillation and atrial flutter in people whose hearts have either returned to normal rhythm or who undergo drug therapy or electric shock treatment i.e. direct current cardioversion (DCCV) to maintain normal rhythm. It is a class III antiarrhythmic drug. In the United States, the FDA approved label includes a claim for reducing hospitalization, but not for reducing mortality, as a reduction in mortality was not demonstrated in the clinical development program. A trial of the drug in heart failure was stopped as an interim analysis showed a possible increase in heart failure deaths, in patients with moderate to severe CHF.

CAS：141626-36-0
中文别名：
英文别名：Dronedarone;N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide;Multaq;UNII-JQZ1L091Y2;
分子式：C31H44N2O5S
分子量：556.756
精确质量：556.297
Psa：97.23
Logp：8.2028

UNII：JQZ1L091Y2

密度：1.143 g/cm3
沸点：683.9ºC at 760 mmHg
闪点：367.4ºC
折射率：1.563
蒸汽压：1.47E-18mmHg at 25°C

海关编码：3004909090